<DOC>
	<DOC>NCT02356341</DOC>
	<brief_summary>This observational study is intended to collect outcome data from a cohort of 90 patients suffering from symptoms of dry eye disease due to meibomian gland dysfunction who are treated with the medical device NovaTears® eye drops for a duration of 6 to 8 weeks.</brief_summary>
	<brief_title>NovaTears® Eye Drops Observational Study NT-002</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>According to NovaTears® instruction for use ≥ 18 years Patients with dry eye disease due to meibomian gland dysfunction applying eye lid hygiene for at least 14 days Ability and willingness to provide written Informed Consent Ability and willingness to participate in all examinations Willingness and ability to return for follow up visit Patients with hypersensitivity to any of the components of NovaTears® Patients with contact lenses, pregnancies, or who are breast feeding Patients with dry eye disease not caused by meibomian gland dysfunction Patients taking lipid containing eye drops or requiring topical pharmacological treatment of dry eye disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>